Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer

This phase II study evaluated the response rate and tolerability of gemcitabine–oxaliplatin chemotherapy in non-small-cell lung cancer (NSCLC) patients. Chemonaive patients with stage IIIB or IV NSCLC received gemcitabine 1000 mg m(−2) on days 1 and 8, followed by oxaliplatin 130 mg m(−2) on day 1....

Descripción completa

Detalles Bibliográficos
Autores principales: Cappuzzo, F, Novello, S, De Marinis, F, Franciosi, V, Maur, M, Ceribelli, A, Lorusso, V, Barbieri, F, Castaldini, L, Crucitta, E, Marini, L, Bartolini, S, Scagliotti, G V, Crinò, L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361475/
https://www.ncbi.nlm.nih.gov/pubmed/15956971
http://dx.doi.org/10.1038/sj.bjc.6602667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361475/
https://www.ncbi.nlm.nih.gov/pubmed/15956971
http://dx.doi.org/10.1038/sj.bjc.6602667

Ejemplares similares